NasdaqGS:IART

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Integra LifeSciences Holdings

Executive Summary

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. More Details


Snowflake Analysis

Moderate growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Integra LifeSciences Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IART has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.9%

IART

-1.1%

US Medical Equipment

-1.4%

US Market


1 Year Return

-21.4%

IART

23.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: IART underperformed the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: IART underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

IARTIndustryMarket
7 Day-0.9%-1.1%-1.4%
30 Day5.3%5.2%4.7%
90 Day-3.6%6.7%8.2%
1 Year-21.4%-21.4%24.8%23.8%20.5%17.8%
3 Year-6.9%-6.9%73.9%69.4%42.2%32.7%
5 Year61.6%61.6%145.2%126.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is Integra LifeSciences Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?

5.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IART ($47.44) is trading below our estimate of fair value ($50.34)

Significantly Below Fair Value: IART is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: IART is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: IART is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IART's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IART is good value based on its PB Ratio (3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

76.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IART is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: IART is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IART's is expected to become profitable in the next 3 years.

Revenue vs Market: IART's revenue (7.3% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: IART's revenue (7.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IART's Return on Equity is forecast to be low in 3 years time (15.5%).


Next Steps

Past Performance

How has Integra LifeSciences Holdings performed over the past 5 years?

9.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IART is currently unprofitable.

Growing Profit Margin: IART is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IART is unprofitable, but has reduced losses over the past 5 years at a rate of 9.5% per year.

Accelerating Growth: Unable to compare IART's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IART is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).


Return on Equity

High ROE: IART has a negative Return on Equity (-0.26%), as it is currently unprofitable.


Next Steps

Financial Health

How is Integra LifeSciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IART's short term assets ($966.2M) exceed its short term liabilities ($212.4M).

Long Term Liabilities: IART's short term assets ($966.2M) do not cover its long term liabilities ($1.8B).


Debt to Equity History and Analysis

Debt Level: IART's debt to equity ratio (122.6%) is considered high.

Reducing Debt: IART's debt to equity ratio has increased from 92.1% to 122.6% over the past 5 years.

Debt Coverage: IART's debt is not well covered by operating cash flow (12.5%).

Interest Coverage: IART is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Pete Arduini (55 yo)

8.75yrs

Tenure

US$7,859,423

Compensation

Mr. Peter J. Arduini, also known as Pete, serves as a Chief Executive Officer at Integra LifeSciences Corporation since January 2012 and also serves as its Director. He joined Integra in November 2010 as p ...


CEO Compensation Analysis

Compensation vs Market: Pete's total compensation ($USD7.86M) is above average for companies of similar size in the US market ($USD5.63M).

Compensation vs Earnings: Pete's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Arduini
President8.75yrsUS$7.86m0.26%
$ 10.3m
Carrie Anderson
Executive VP & CFO1.33yrsUS$2.41m0.040%
$ 1.6m
Glenn Coleman
Executive VP & COO1.33yrsUS$3.12m0.054%
$ 2.2m
Eric Schwartz
Executive VP1.92yrsUS$2.25m0.039%
$ 1.6m
Robert Davis
Executive VP and President of Orthopedics & Tissue Technologies7.83yrsUS$1.39m0.053%
$ 2.1m
Richard Caruso
Founder and Chairman Emeritus3.42yrsUS$37.50k0.20%
$ 8.0m
Jeffrey Mosebrook
Senior VP3yrsno data0.0079%
$ 315.0k
Kenneth Burhop
Corporate VP & Chief Scientific Officer6.67yrsno data0.018%
$ 716.4k
William Compton
Chief Information Officer & Senior VPno datano datano data
Sravan Emany
Senior Vice President of Strategy2.67yrsno datano data
Laurene Isip
Senior Director of Global Corporate Communications & Public Relationsno datano datano data
Maria Platsis
Senior Vice President of Corporate Developmentno datano datano data

3.0yrs

Average Tenure

53.5yo

Average Age

Experienced Management: IART's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Arduini
President8.75yrsUS$7.86m0.26%
$ 10.3m
Richard Caruso
Founder and Chairman Emeritus3.42yrsUS$37.50k0.20%
$ 8.0m
Raymond Murphy
Independent Director11.5yrsUS$247.55k0.089%
$ 3.5m
Donald Morel
Independent Director7.17yrsUS$280.05k0.058%
$ 2.3m
Christian Schade
Independent Director14.75yrsUS$298.80k0.050%
$ 2.0m
Stuart Essig
Independent Chairman of the Board8.75yrsUS$347.53k2.24%
$ 89.6m
Barbara Hill
Independent Presiding Director2.08yrsUS$305.06k0.087%
$ 3.5m
Keith N. Bradley
Independent Director28.75yrsUS$265.05k0.059%
$ 2.4m
Rhonda Ballintyn
Independent Director1.75yrsUS$339.63k0.018%
$ 701.6k
Lloyd Howell
Independent Director7.58yrsUS$265.05k0.053%
$ 2.1m

8.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: IART's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IART insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integra LifeSciences Holdings Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integra LifeSciences Holdings Corporation
  • Ticker: IART
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.998b
  • Shares outstanding: 84.27m
  • Website: https://www.integralife.com

Number of Employees


Location

  • Integra LifeSciences Holdings Corporation
  • 1100 Campus Road
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IARTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1995
IL3DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1995

Biography

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 23:35
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.